Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Diabetes Obes Metab. 2024 Nov;26(11):4933-4944. doi: 10.1111/dom.15894. Epub 2024 Aug 27.
To evaluate the relationship between the stress-hyperglycaemia ratio (SHR) and the clinical prognosis of patients with moderate-to-severe coronary artery calcification (MSCAC).
We consecutively enrolled 3841 patients with angiography-detected MSCAC. The individuals were categorized into three groups based on SHR tertiles: T1 (SHR ≤ 0.77), T2 (0.77 < SHR ≤ 0.89) and T3 (SHR > 0.89). The SHR value was calculated using the formula SHR = [admission glucose (mmol/L)]/[1.59 × HbA1c (%) - 2.59]. The primary outcomes were major adverse cardiovascular and cerebrovascular events (MACCEs), including all-cause death, non-fatal myocardial infarction and non-fatal stroke.
During a median follow-up of 3.11 years, 241 MACCEs were recorded. Kaplan-Meier survival analysis showed that the SHR T3 group had the highest incidence of MACCEs (P < .001). Moreover, findings from the restricted cubic spline analysis showed a significant and positive association between the SHR and MACCEs. This correlation remained consistent even after considering other variables that could potentially impact the results (P = .794). When comparing SHR T1 with SHR T3, it was found that SHR T3 was significantly associated with an increased risk of the primary outcome (adjusted hazard ratio = 1.50; 95% confidence interval: 1.10-2.03).
Patients with MSCAC showed a positive correlation between the SHR and MACCE rate over a 3-year follow-up period. The study showed that an SHR value of 0.83 is the key threshold, indicating a poor prognosis. Future large-scale multicentre investigations should be conducted to determine the predictive value of the SHR in patients with MSCAC.
评估应激-高血糖比值(SHR)与中重度冠状动脉钙化(MSCAC)患者临床预后的关系。
连续纳入 3841 例经血管造影证实的 MSCAC 患者。根据 SHR 三分位将患者分为三组:T1 组(SHR≤0.77)、T2 组(0.77<SHR≤0.89)和 T3 组(SHR>0.89)。采用公式 SHR=〔入院时血糖(mmol/L)〕/〔1.59×糖化血红蛋白(%)-2.59〕计算 SHR 值。主要终点事件为主要不良心脑血管事件(MACCE),包括全因死亡、非致死性心肌梗死和非致死性卒中。
中位随访 3.11 年期间,记录到 241 例 MACCE。Kaplan-Meier 生存分析显示,SHR T3 组 MACCE 发生率最高(P<0.001)。此外,受限立方样条分析结果表明,SHR 与 MACCE 之间存在显著正相关。即使考虑其他可能影响结果的变量后,这种相关性仍然一致(P=0.794)。与 SHR T1 相比,SHR T3 与主要结局风险增加显著相关(校正后危险比=1.50;95%置信区间:1.10-2.03)。
在 3 年随访期间,MSCAC 患者的 SHR 与 MACCE 发生率呈正相关。研究表明,SHR 值为 0.83 是一个关键的阈值,提示预后不良。未来应开展大规模多中心研究,以确定 SHR 在 MSCAC 患者中的预测价值。